Namwiwat Medical (NAM) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Namwiwat Medical stock THB 2.64, price THB 3.04, that is 13.2% below the price, quality 46 out of 100. Rating: overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
36‑month range 2.96 THB – 6.68 THB · fair‑value band 1.97 THB – 3.43 THB · the 3.04 THB price screens above the 2.64 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Namwiwat Medical in your weekly email
Every Wednesday you see whether Namwiwat Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Namwiwat Medical Corporation Public Company Limited manufactures and distributes medical equipment in Thailand. The company offers steam and low temperature sterilizers, instrument washer disinfectors, ultrasonic cleaning systems, and drying cabinets, as well as waste sterilizers.
Show moreShow less
It also provides NAMTrack, a central sterile supply department software management product, as well as Air Track. In addition, the company offers air and surface disinfection equipment and air purifiers.
Further, it provides medical supplies, disinfection services, medical equipment maintenance services, infectious waste services, and other medical services. The company was founded in 1970 and is based in Samut Prakan, Thailand.
Stock analysis
Namwiwat Medical (NAM) currently trades at 3.04 THB, while our model-based Fair Value estimate is 2.64 THB, 13% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 3.80 THB per share, and 6 of the 17 models we run sit above the 3.04 THB price.
Bear case: the Asset-Based group reads lowest at 1.67 THB, and 11 of the 17 models stay below the price. Data coverage for this calculation is low.
Scenario range: 1.97 THB (bear) to 3.43 THB (bull), the price of 3.04 THB sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Namwiwat Medical reported revenue of 1.9B THB in FY2026 versus 992M THB in FY2022, a compound +17.2%/yr. Reported net income was 102M THB in FY2026, compounding −12.7%/yr from FY2022.
Key figures
Market cap 2.1B THB (≈ $63.6M) Micro · P/E ratio 25.3 · P/S ratio 1.23 · EPS (TTM) 0.1200 THB · Dividend yield 4.3% · Net margin 4.8% · Return on equity 4.0% · Return on assets (EBIT) 11.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (medium confidence).
What moves the price
The share trades about 20% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −13%, NAM screens cheaper than that median.
Fair Value models
Bear1.97 THBFair Value 2.64 THBBull3.43 THB
Price 3.04 THB · Downside -13.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+67.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.4%
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in THB ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in THB: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−3.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−7.5%
Dividend (yield on the price)4.3%
Profit margin 2022 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.23% → 8%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside−10.8% · Above median
Profitability
Return on equity (12 months)4.0% · Below median
Return on assets3.3% · Above median
Net margin (12 months)4.8% · Below median
Operating margin (12 months)8.8% · Below median
Growth and dividend
Revenue growth (quarter YoY)−5.2% · Bottom 25%
Dividend yield (12 months)4.3% · Top 25%
Balance sheet
Debt / equity0.04× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Namwiwat Medical Fair Value". https://www.fairvalue-calculator.com/stock/NAM
Frequently asked questions
Is Namwiwat Medical (NAM) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 2.64 THB versus a price of 3.04 THB, about 13% lower (overvalued).
What is the fair value of NAM?
Our model-based fair value for Namwiwat Medical is 2.64 THB (as of Nov 8, 2026), built from audited fundamentals. The current price: 3.04 THB.
What is the quality score of NAM?
Namwiwat Medical has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Namwiwat Medical (NAM)?
Our model-based price target is the fair value of 2.64 THB (as of Nov 8, 2026) from 17 valuation models. Cautious scenario 1.97 THB, optimistic scenario 3.43 THB. It is a calculation from audited fundamentals, not an analyst target.
What is the Namwiwat Medical stock forecast for 2026?
Our models put fair value at 2.64 THB, about 13% lower versus a price of 3.04 THB (overvalued). Cautious scenario 1.97 THB, optimistic scenario 3.43 THB. The calculation is refreshed regularly with new filings.
What is the revenue of Namwiwat Medical (NAM)?
Namwiwat Medical reported trailing-twelve-month revenue of about 1.7B THB (latest available figure, as of Nov 8, 2026).
Does Namwiwat Medical pay a dividend?
Namwiwat Medical currently shows a dividend yield of 4.28% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Namwiwat Medical (NAM) and when is the ex-dividend date?
Namwiwat Medical pays a dividend of 0.13 THB per share a year, a dividend yield of 4.3%. The last ex-dividend date was Mar 13, 2026. The payout ratio is 108% of earnings. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What is the intrinsic value of Namwiwat Medical (NAM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Namwiwat Medical it is 2.64 THB per share (as of Nov 8, 2026), against a price of 3.04 THB. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Namwiwat Medical stock overvalued or undervalued in 2026?
As of Nov 8, 2026, NAM trades above its calculated fair value: price 3.04 THB, fair value 2.64 THB, a gap of about −13% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NAM?
No. The price is what the market pays today (3.04 THB); the fair value is what the company's own numbers justify (2.64 THB). For Namwiwat Medical the two are 0.4000 THB per share apart. That gap is exactly why we show both numbers side by side.
How much is Namwiwat Medical worth?
The market values Namwiwat Medical at about 2.1B THB (market capitalisation, as of Nov 8, 2026). Per share that is 3.04 THB; our models calculate a fair value of 2.64 THB per share.
What do the bullish and bearish scenarios say about NAM?
Our models span a range for Namwiwat Medical: cautious scenario 1.97 THB, base 2.64 THB, optimistic 3.43 THB per share (as of Nov 8, 2026, price 3.04 THB). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NAM?
Namwiwat Medical trades at a price-to-earnings ratio of 25.3 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 2.64 THB is built from several models across several years. Other multiples: P/B 1.0, P/S 1.2, EV/EBITDA 8.9.
How solid is the balance sheet of Namwiwat Medical (NAM)?
Balance-sheet figures for Namwiwat Medical (as of Nov 8, 2026): return on equity 4.0%, debt of 0.04 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is NAM from its 52-week high?
Namwiwat Medical trades at 3.04 THB, about 20% below its 52-week high of 3.81 THB and 3% above the low of 2.96 THB (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 2.64 THB is for.
Which stocks are comparable to Namwiwat Medical?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Namwiwat Medical stock attractive at the current price?
The data as of Nov 8, 2026: price 3.04 THB, calculated fair value 2.64 THB (−13%), Quality Score 46/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NAM calculated?
We run Namwiwat Medical through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 2.64 THB builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Namwiwat Medical itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Namwiwat Medical (NAM)?
The closing price on Nov 9, 2026 was 3.04 THB. Our model-based fair value is 2.64 THB, about 13% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Namwiwat Medical right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Namwiwat Medical
How large is the market capitalisation of Namwiwat Medical (NAM)?
The market capitalisation of Namwiwat Medical is 2.1B THB (≈ $63.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Namwiwat Medical (NAM)?
The price-to-sales ratio of Namwiwat Medical is 1.23 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Namwiwat Medical (NAM)?
Earnings per share at Namwiwat Medical are 0.1200 THB (price ÷ EPS = P/E 25.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Namwiwat Medical (NAM)?
The dividend yield of Namwiwat Medical is 4.3% (payout 108%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Namwiwat Medical (NAM)?
The net margin of Namwiwat Medical is 4.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Namwiwat Medical (NAM)?
The return on equity (ROE) of Namwiwat Medical is 4.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Namwiwat Medical (NAM)?
On an EBIT basis the return on assets of Namwiwat Medical is 11.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Namwiwat Medical (NAM)?
The operating margin of Namwiwat Medical is 8.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Namwiwat Medical (NAM)?
Revenue at Namwiwat Medical is growing −5.2% versus a year earlier (3y avg +19.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Namwiwat Medical (NAM)?
Earnings per share at Namwiwat Medical are growing +137% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Namwiwat Medical (NAM) generate?
The free cash flow of Namwiwat Medical is −30.8M THB (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Namwiwat Medical (NAM) carry?
The net debt of Namwiwat Medical is 190M THB (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Namwiwat Medical in the live analysis
One click puts Namwiwat Medical on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026